Related Experiment Video

Updated: Jan 4, 2026

Clinical Application of Sleeping Beauty and Artificial Antigen Presenting Cells to Genetically Modify T Cells from Peripheral and Umbilical Cord Blood
09:29

Clinical Application of Sleeping Beauty and Artificial Antigen Presenting Cells to Genetically Modify T Cells from Peripheral and Umbilical Cord Blood

Published on: February 1, 2013

18.9K

Engineering strategies for generating hypoimmunogenic cells with high clinical and commercial value

Nafees N Malik1,2, Annalisa M Jenkins1, Jim Mellon2

  • 1AgeX Therapeutics, Inc., Alameda, CA 94501, USA.

Regenerative Medicine
|October 31, 2019
PubMed
Abstract

No abstract available in PubMed .

Keywords:
CD47HLA-EHLA-GPD-L1human leukocyte antigen (HLA)hypoimmunogenic cellsimmune rejectionimmune toleranceimmunogenicityuniversal cells

More Related Videos

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant08:52

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant

Published on: May 27, 2011

17.7K
Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates06:10

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Published on: May 9, 2025

840

Related Concept Videos

Hybridoma Technology01:31

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
17.0K